Feedback / Questions
Tevimbra (tislelizumab-jsgr) - BeiGene
Tevimbra: Regulatory approval in Japan for 1L gastric cancer in 2026
(BeiGene)
-
Mar 1, 2025 -
Q4 2024 Results
Japan approval
•
Gastric Cancer • Gastrointestinal Cancer • Oncology
https://ir-api.eqs.com/media/document/6d80cd79-1b6f-4b3f-a71e-f4c6b04211ff/assets/BGNE-Earnings_Presentation_Q4_FY_2024_final.pdf?disposition=inline
Mar 1, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious